AU2007223962A1 - Meridamycin analogues for the treatment of neurodegenerative disorders - Google Patents

Meridamycin analogues for the treatment of neurodegenerative disorders Download PDF

Info

Publication number
AU2007223962A1
AU2007223962A1 AU2007223962A AU2007223962A AU2007223962A1 AU 2007223962 A1 AU2007223962 A1 AU 2007223962A1 AU 2007223962 A AU2007223962 A AU 2007223962A AU 2007223962 A AU2007223962 A AU 2007223962A AU 2007223962 A1 AU2007223962 A1 AU 2007223962A1
Authority
AU
Australia
Prior art keywords
alkyl
substituted
compound
heterocyclyl
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007223962A
Other languages
English (en)
Inventor
Edmund Idris Graziani
Kevin Pong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2007223962A1 publication Critical patent/AU2007223962A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2007223962A 2006-03-07 2007-03-05 Meridamycin analogues for the treatment of neurodegenerative disorders Abandoned AU2007223962A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77994006P 2006-03-07 2006-03-07
US60/779,940 2006-03-07
PCT/US2007/005645 WO2007103347A1 (en) 2006-03-07 2007-03-05 Meridamycin analogues for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
AU2007223962A1 true AU2007223962A1 (en) 2007-09-13

Family

ID=38289934

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007223962A Abandoned AU2007223962A1 (en) 2006-03-07 2007-03-05 Meridamycin analogues for the treatment of neurodegenerative disorders

Country Status (19)

Country Link
US (1) US7745457B2 (enExample)
EP (1) EP1991551A1 (enExample)
JP (1) JP2009529049A (enExample)
KR (1) KR20080099317A (enExample)
CN (1) CN101426796A (enExample)
AR (1) AR059738A1 (enExample)
AU (1) AU2007223962A1 (enExample)
BR (1) BRPI0708611A2 (enExample)
CA (1) CA2643350A1 (enExample)
CR (1) CR10272A (enExample)
EC (1) ECSP088718A (enExample)
IL (1) IL193414A0 (enExample)
MX (1) MX2008011312A (enExample)
NO (1) NO20083695L (enExample)
PE (1) PE20081550A1 (enExample)
RU (1) RU2008132779A (enExample)
TW (1) TW200804400A (enExample)
WO (1) WO2007103347A1 (enExample)
ZA (1) ZA200807678B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828203A2 (en) * 2004-12-20 2007-09-05 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
RU2394036C2 (ru) * 2004-12-20 2010-07-10 Вайет Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) 1993-02-02 1993-03-17 Sandoz Ltd Compounds
GB9318144D0 (en) 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US20050197356A1 (en) * 2004-03-02 2005-09-08 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
BRPI0508224A (pt) 2004-03-02 2007-07-17 Wyeth Corp composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto
JP2008501342A (ja) 2004-06-03 2008-01-24 ワイス 複合ポリケチドを生成するための生合成遺伝子クラスター
US7595187B2 (en) * 2004-11-12 2009-09-29 Wyeth Elaiophylin biosynthetic gene cluster
EP1828203A2 (en) 2004-12-20 2007-09-05 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
RU2394036C2 (ru) 2004-12-20 2010-07-10 Вайет Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний

Also Published As

Publication number Publication date
ZA200807678B (en) 2009-08-26
US7745457B2 (en) 2010-06-29
KR20080099317A (ko) 2008-11-12
RU2008132779A (ru) 2010-04-20
EP1991551A1 (en) 2008-11-19
CA2643350A1 (en) 2007-09-13
CR10272A (es) 2008-10-03
MX2008011312A (es) 2008-09-12
US20070213525A1 (en) 2007-09-13
WO2007103347A1 (en) 2007-09-13
ECSP088718A (es) 2008-10-31
BRPI0708611A2 (pt) 2011-06-07
TW200804400A (en) 2008-01-16
NO20083695L (no) 2008-10-03
CN101426796A (zh) 2009-05-06
PE20081550A1 (es) 2008-12-31
IL193414A0 (en) 2009-05-04
AR059738A1 (es) 2008-04-23
JP2009529049A (ja) 2009-08-13

Similar Documents

Publication Publication Date Title
AU2022271425B2 (en) Processes of making and crystalline forms of a MDM2 inhibitor
JP5738457B2 (ja) 化合物
CN108135912B (zh) 孕甾醇及其使用方法
RU2397985C2 (ru) Новые полиморфные формы рифаксимина, способы их получения и их применение в лекарственных препаратах
WO2024153119A1 (en) Kras g12d inhibitors and uses thereof
MX2007010892A (es) Isomero de oxepano de 42-o-(2-hidroxi)etil-rapamicina.
KR101289998B1 (ko) 유기 화합물
US7745457B2 (en) Meridamycin analogues for the treatment of neurodegenerative disorders
EP3773577B1 (en) Tricyclic ask1 inhibitors
EP4361148A1 (en) Heterocycloalkyl-substituted polyheteroazole derivative as medical drug for treatment and/or prevention of rs virus infectious disease
RU2686675C1 (ru) Таксановые соединения, а также способ их получения и их применения
JP2019014683A (ja) 多能性幹細胞からのテラトーマ形成抑制剤及びその用途
CN116669721B (zh) 抗胆碱能药物
HK40129060A (en) Substituted n-(4-trifluoromethyl)-2-cyano crotonamide compound and preparation method, pharmaceutical composition and application thereof
CN120192247A (zh) 取代n-(4-三氟甲基)-2-氰基巴豆酰胺化合物及其制备方法、药物组合及用途
EA050745B1 (ru) Применение бициклических соединений для лечения заболеваний
CN119866332A (zh) 铁死亡抑制剂-吩噁嗪乙酰胺
NZ753956B2 (en) Processes of making and crystalline forms of a mdm2 inhibitor
HK1226052A1 (en) Crystalline form of a mdm2 inhibitor
HK1226052B (en) Crystalline form of a mdm2 inhibitor

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period